State Street Corp Purchases 11,566 Shares of Atea Pharmaceuticals, Inc. (NASDAQ:AVIR)

State Street Corp raised its stake in shares of Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) by 0.7% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,733,486 shares of the company’s stock after purchasing an additional 11,566 shares during the quarter. State Street Corp owned 2.05% of Atea Pharmaceuticals worth $5,807,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also recently bought and sold shares of the stock. Intech Investment Management LLC acquired a new stake in Atea Pharmaceuticals in the third quarter worth about $36,000. Dynamic Technology Lab Private Ltd bought a new position in shares of Atea Pharmaceuticals during the 3rd quarter valued at about $37,000. China Universal Asset Management Co. Ltd. lifted its stake in Atea Pharmaceuticals by 64.1% in the third quarter. China Universal Asset Management Co. Ltd. now owns 16,237 shares of the company’s stock valued at $54,000 after buying an additional 6,343 shares in the last quarter. SG Americas Securities LLC raised its stake in shares of Atea Pharmaceuticals by 117.9% in the 3rd quarter. SG Americas Securities LLC now owns 30,612 shares of the company’s stock valued at $103,000 after purchasing an additional 16,561 shares during the period. Finally, The Manufacturers Life Insurance Company grew its stake in shares of Atea Pharmaceuticals by 14.2% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 34,886 shares of the company’s stock worth $115,000 after acquiring an additional 4,339 shares in the last quarter. 86.67% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Atea Pharmaceuticals

In other Atea Pharmaceuticals news, Director Franklin M. Berger sold 359,606 shares of the business’s stock in a transaction that occurred on Tuesday, December 10th. The shares were sold at an average price of $2.85, for a total transaction of $1,024,877.10. Following the sale, the director now directly owns 451,897 shares of the company’s stock, valued at $1,287,906.45. The trade was a 44.31 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 17.80% of the stock is currently owned by insiders.

Atea Pharmaceuticals Price Performance

Shares of NASDAQ:AVIR opened at $3.33 on Friday. The stock has a market capitalization of $281.26 million, a PE ratio of -1.61 and a beta of 0.20. Atea Pharmaceuticals, Inc. has a one year low of $2.75 and a one year high of $4.60. The company’s 50-day moving average price is $3.28 and its two-hundred day moving average price is $3.48.

Atea Pharmaceuticals (NASDAQ:AVIR) last posted its earnings results on Thursday, November 7th. The company reported ($0.37) EPS for the quarter, beating the consensus estimate of ($0.50) by $0.13. During the same period last year, the company posted ($0.40) earnings per share. On average, analysts anticipate that Atea Pharmaceuticals, Inc. will post -2.01 earnings per share for the current fiscal year.

Atea Pharmaceuticals Profile

Atea Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19.